Reading KRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRMD free→Reading KRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KRMD free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 52% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. If KRMD cuts guidance on the next call, that could lead to a meaningful negative impact. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.94. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.87 KRMD trades at 4× p/s — 1.5× the 3× p/s peer median. The market is re-rating it beyond its own range; our $8.27 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 53% below a flat-multiple fair value, below our forecast of about 16%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.31x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.01. 0 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$175.
How much price usually moves either way.
On a bad day, this stock has moved -$442.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,126.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Faster growth in healthcare could help KORU Medical do better.
Confirms:The healthcare sector is showing revenue growth going back to 10% or more.
Disproves:Healthcare sector revenue growth keeps slowing down below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for KRMD yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. (a) Public Announcement or Release . On May 6, 2026, KORU Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026 and reiterating financial guidance for the fiscal year ended December 31, 2026. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A related conference call will be held on May 6, 2026 at 4:30pm Eastern Tim…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
KRMD KORU Medical Systems, Inc. | Typical Show detailsSector percentile: 44 of 100 | inexpensive | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 93 of 100 | fair | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve positive adjusted EBITDA and positive cash flow for the full year 2026.
The company aims to maintain a gross margin between 61% and 63% for the full year 2026.
The company targets net revenue growth of 15% to 22% for the full year 2026.
Why it matters: The earnings report will show if KORU Medical can improve its loss-making status.
Confirms one read:Earnings report shows a reduction in losses compared to the previous quarter.
Confirms the other:Earnings report shows losses increasing or staying the same compared to the previous quarter.
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. Reference is made to the disclosure under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Linda Tharby, President and Chief Executive Officer of KORU Medical Systems, Inc. (the “Company”), has announced her retirement as Chief Executive Officer effective June 30, 2026 (the “Transition Date”). Mr. Kalbermatten has been appointed to replace Ms. Tharby as the Company’s President effective March 15, 2026 and will succeed Ms. Tharby as Chief…
CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. On March 30, 2026, KORU Medical Systems, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its loan and security agreement, by and between the Company and HSBC Ventures USA Inc., as lender, dated March 8, 2024, as amended (the “Loan and Security Agreement”), relating to a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “R…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. (a) Public Announcement or Release . On March 12, 2026, KORU Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and full year ended December 31, 2025 and financial guidance for the fiscal year ended December 31, 2026. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A related conference call will be held on March 12, 2026 at 4:30pm…